[HTML][HTML] BRCA mutations in prostate cancer: assessment, implications and treatment considerations
S Shah, R Rachmat, S Enyioma, A Ghose… - International Journal of …, 2021 - mdpi.com
Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …
implicated in cancer and DNA damage response (DDR) pathways are in place against this …
[HTML][HTML] BRCA2 and other DDR genes in prostate cancer
Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent
in prostate cancer than previously recognized, with BRCA2 as the most commonly altered …
in prostate cancer than previously recognized, with BRCA2 as the most commonly altered …
BRCA mutations in prostate cancer: prognostic and predictive implications
C Messina, C Cattrini, D Soldato, G Vallome… - Journal of …, 2020 - Wiley Online Library
Despite chemotherapy and novel androgen‐receptor signalling inhibitors (ARSi) have been
approved during the last decades, metastatic castration‐resistant prostate cancer (mCRPC) …
approved during the last decades, metastatic castration‐resistant prostate cancer (mCRPC) …
[HTML][HTML] PARP inhibitors in prostate cancer–the preclinical rationale and current clinical development
Prostate cancer is globally the second most commonly diagnosed cancer type in men.
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …
Recent studies suggest that mutations in DNA repair genes are associated with aggressive …
[HTML][HTML] BRCA mutations in ovarian and prostate cancer: bench to bedside
Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
EN Risdon, CH Chau, DK Price, O Sartor… - The oncologist, 2021 - academic.oup.com
Abstract The US Food and Drug Administration recently approved two poly‐adenosine
diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of …
diphosphate‐ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of …
[HTML][HTML] Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic
A Ghose, M Moschetta, G Pappas-Gogos… - International Journal of …, 2021 - mdpi.com
Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-
scale sequencing efforts, there is currently a better understanding of the genomic landscape …
scale sequencing efforts, there is currently a better understanding of the genomic landscape …
[HTML][HTML] BRCA germline mutations in prostate cancer: the future is tailored
Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading
cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment …
cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment …
[HTML][HTML] Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
R Lozano, E Castro, IM Aragón, Y Cendón… - British journal of …, 2021 - nature.com
Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …
response and repair (DDR) genes are present in a significant proportion of patients with …
[HTML][HTML] A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
SH Lang, SL Swift, H White… - International …, 2019 - spandidos-publications.com
Several ongoing international prostate cancer (PC) clinical trials are exploring therapies that
target the DNA damage response (DDR) pathway. This systematic review summarizes the …
target the DNA damage response (DDR) pathway. This systematic review summarizes the …